GROWTH-HORMONE AXIS & LONGEVITY RESEARCH
Research Peptide Fundamentals research peptides
Four compounds at the intersection of the GH axis and the biology of cellular aging — one endogenous coenzyme, two GH secretagogues, one mitochondrial-encoded peptide. Summarized from the peer-reviewed literature, with citations.
Ipamorelin
A selective GHS-R1a agonist that pulses growth hormone without raising cortisol or prolactin — the cleanest GHRP studied in humans, with one failed Phase 2 trial.
Read the research →
CJC-1295
A long-acting GHRH analog that keeps GH and IGF-1 elevated for days after a single dose — pharmacologically well-characterized in humans, never approved anywhere.
Read the research →
NAD+
The cell's central redox coenzyme and a consumed substrate for sirtuins and PARPs. Tissue levels fall with age; the most clinically tested compound on this desk.
Read the research →
MOTS-c
A 16-amino-acid peptide encoded in the mitochondrial genome — an exercise-inducible regulator of AMPK and glucose metabolism that translocates to the nucleus under stress.
Read the research →The short version
pureformpeptide is a reading desk, not a store. It covers four research compounds that keep showing up in the same conversation — about how the body ages, how growth hormone declines, and whether cellular biology can be supported by external molecules. A peptide is a short chain of amino acids, far smaller than a protein; the other compound here, NAD+, is not a peptide at all but an endogenous molecule that every cell in your body depends on to make energy and repair DNA.
This desk does one job: it tells you, in plain language and with numbered citations, what each compound was actually studied for, in which species, and how far that evidence reaches into human beings. Most of the peptide research stops well short of controlled human trials. None of these compounds is an approved medicine. We never list a human dose or give any form of medical advice. Read each compound page and then see how they compare on the compare these peptides page.
What this desk covers
The four compounds here were chosen because they each illuminate a different part of the growth-hormone axis and longevity research landscape:
- NAD+ is the lead — an endogenous dinucleotide that powers cell metabolism and fuels the sirtuin and PARP enzymes central to DNA repair and cellular aging. It is categorized as a dietary supplement (or its precursors are), not a drug, and it has the most extensive human clinical trial record of the four [11][12][13].
- Ipamorelin is a selective GH secretagogue, a synthetic pentapeptide that activates the ghrelin receptor on pituitary cells to pulse growth hormone — without the cortisol and prolactin side effects of earlier peptides in its class [3][4].
- CJC-1295 works at the GHRH receptor rather than the ghrelin receptor, driving sustained multi-day elevation of both GH and IGF-1. Its long-acting DAC form is a pharmacological contrast to the brief pulse that ipamorelin produces [9][10].
- MOTS-c sits furthest from the clinic: a 16-amino-acid peptide encoded inside mitochondrial DNA, released during exercise, that activates AMPK through an unusual folate-cycle mechanism and travels to the nucleus under metabolic stress [20][22].
The growth-hormone axis and longevity research, side by side
Why frame these four together? Because they each address a different node in the same biological question: what happens to energy production, growth-factor signaling, and cellular repair as the body ages — and is any of that reversible?
The GH axis declines with age (somatopause). NAD+ falls across tissues (partly because the NAD-consuming enzyme CD38 rises) [16]. MOTS-c expression from mitochondria is inducible by exercise and may encode one of the body's signals for metabolic adaptation [21]. GH secretagogues like Ipamorelin and CJC-1295 were originally investigated to restore GH pulsatility — the FDA reviewed them both for this class-level question and found neither qualified for compounding pharmacy access.
Covering them side by side lets a reader see both the convergences — the GH/IGF-1/AMPK/sirtuin cluster that keeps appearing in longevity research — and the important differences in evidence quality. NAD+ precursors have multicenter RCTs [12]; CJC-1295 has early human PK studies [9]; MOTS-c's interventional evidence is entirely in mice [21]. This desk holds those distinctions plainly in view.
What are research peptides?
A peptide is a chain of amino acids — the same building blocks that proteins are made from, only far shorter. Most peptides in the body act as signaling molecules: hormones, neurotransmitters, or intracellular messengers. A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, and occasionally in early human trials — but has not been approved by a regulatory body as a medicine.
Sellers describe these compounds as being for laboratory research use only. That framing is not just legal language: it reflects a real gap in the evidence. Dosing, long-term safety, and real-world effectiveness in people are largely uncharacterized for most research peptides. When this site reports a finding, it reports it exactly as the study did — for example, studied at 0.5 mg/kg/day subcutaneously in 22-month-old mice — and never as a recommendation for what any person should do.